TY - JOUR
T1 - Trends of hepatitis B virus genotype distribution in chronic hepatitis B patients in Japan
AU - Sakamoto, Kazumasa
AU - Ito, Kiyoaki
AU - Yotsuyanagi, Hiroshi
AU - Yatsuhashi, Hiroshi
AU - Tanaka, Yasuhito
AU - Hige, Shuhei
AU - Takikawa, Yasuhiro
AU - Ueno, Yoshiyuki
AU - Yamamoto, Kazuhide
AU - Imazeki, Fumio
AU - Inoue, Jun
AU - Kurosaki, Masayuki
AU - Umemura, Takeji
AU - Toyoda, Hidenori
AU - Mita, Eiji
AU - Michitaka, Kojiro
AU - Maeshiro, Tatsuji
AU - Yamada, Norie
AU - Suetsugu, Atsushi
AU - Kawanaka, Miwa
AU - Seko, Yuya
AU - Matsuura, Kentaro
AU - Okumura, Akinori
AU - Fukuzawa, Yoshitaka
AU - Sugiyama, Masaya
AU - Mizokami, Masashi
AU - Yoneda, Masashi
N1 - Funding Information:
KI and MY received research funding from AbbVie, Bayer Pharma, EA pharma, Otsuka Pharmaceutical, and Sumitomo Pharmaceutical. JI received research funding from AbbVie. YT received honorariums from FUJIREBIO inc., Gilead Sciences Inc, and GlaxoSmithKline PLC. YT also received research funding from FUJIFILM Corporation, Janssen Pharmaceutical K. K., Gilead Sciences Inc, Board of Trustees of the Leland, Stanford Junior University, GlaxoSmithKline PLC., FUJIREBIO inc., Sysmex Corp. YU received honorariums from Gilead Sciences and AbbVie Inc. YU also received research funding from AbbVie Inc. MK received honorariums from Gilead Sciences, AbbVie, Chugai, Eisai, Bayer, Lilly, and Otsuka. TU received honorariums from AbbVie and also received research funding from AbbVie and Tosoh Corporation. TM received research funding from IQVIA solutions. MY received honorariums from Otsuka pharmaceutical and Sumitomo pharmaceutical.
Funding Information:
This work was supported by “AMED Program on the Innovative Development and the Application of New Drugs for Hepatitis B under Grant Number JP20fk0310118, JP21fk0310118h0005 and JP22fk0310502h0001,” “The Japanese Society of Gastroenterology Grant,” and “JSPS KAKENHI Grant Number JP19K08479”.
Publisher Copyright:
© 2022, Japanese Society of Gastroenterology.
PY - 2022/12
Y1 - 2022/12
N2 - Background: Hepatitis B virus (HBV) is one of the most prevalent chronic viral infections that causes chronic hepatitis B (CHB). In Japan, genotypes B and C account for most of acute and chronic cases of hepatitis. However, previous studies showed that the prevalence of genotype A in CHB gradually increased every 5 years. Therefore, we have conducted a nationwide survey to comprehensively investigate the trends of HBV genotype distribution in CHB patients in Japan. Methods: 4421 CHB patients were recruited between 2015 and 2016. Clinical characteristics and distribution of CHB patients among different age groups and genotypes in 2015–2016 was compared with those in 2000–2001, 2005–2006, and 2010–2011. Results: The percentages of genotype A, B, C, and D were 4.0, 16.2, 79.1, and 0.7%, respectively. While the overall percentage of CHB patients with genotype A did not change in the past 5 years, CHB with genotype A increased in young adults. On the other hand, the peak distribution of CHB with genotypes B and C, two genotypes with the largest patient population, has shifted to an older age group. Conclusions: In Japan, the peak distribution for CHB with genotypes B and C advanced to an older age group while CHB with genotype A expanded in a younger age group. Given the universal HBV vaccination launch in Japan in 2016, these pre-vaccination survey data provide important baseline information for comparative studies of the impact of universal vaccination on HBV genotypes.
AB - Background: Hepatitis B virus (HBV) is one of the most prevalent chronic viral infections that causes chronic hepatitis B (CHB). In Japan, genotypes B and C account for most of acute and chronic cases of hepatitis. However, previous studies showed that the prevalence of genotype A in CHB gradually increased every 5 years. Therefore, we have conducted a nationwide survey to comprehensively investigate the trends of HBV genotype distribution in CHB patients in Japan. Methods: 4421 CHB patients were recruited between 2015 and 2016. Clinical characteristics and distribution of CHB patients among different age groups and genotypes in 2015–2016 was compared with those in 2000–2001, 2005–2006, and 2010–2011. Results: The percentages of genotype A, B, C, and D were 4.0, 16.2, 79.1, and 0.7%, respectively. While the overall percentage of CHB patients with genotype A did not change in the past 5 years, CHB with genotype A increased in young adults. On the other hand, the peak distribution of CHB with genotypes B and C, two genotypes with the largest patient population, has shifted to an older age group. Conclusions: In Japan, the peak distribution for CHB with genotypes B and C advanced to an older age group while CHB with genotype A expanded in a younger age group. Given the universal HBV vaccination launch in Japan in 2016, these pre-vaccination survey data provide important baseline information for comparative studies of the impact of universal vaccination on HBV genotypes.
KW - Chronic hepatitis B
KW - Genotype
KW - Geographical distribution
KW - Hepatitis B virus
KW - Trend of genotype
UR - http://www.scopus.com/inward/record.url?scp=85139135308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139135308&partnerID=8YFLogxK
U2 - 10.1007/s00535-022-01921-4
DO - 10.1007/s00535-022-01921-4
M3 - Article
C2 - 36173513
AN - SCOPUS:85139135308
SN - 0944-1174
VL - 57
SP - 971
EP - 980
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 12
ER -
